Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2008-05-19 Board/Management Inform…
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Phosphagenics` Executive Appointment 2 pages ?Kb
Board/Management Information Classification · 100% confidence The document is a company announcement dated 20 May 2008 about the appointment of a new senior executive, Fred Banti, as Senior Vice President and Chief Business Officer. It provides background information on the appointee's experience and the company's business focus. There are no financial statements, regulatory filings, voting results, or other report types present. The content clearly relates to a change in senior management. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 3886 characters, which is consistent with a typical management announcement rather than a full report or regulatory filing.
2008-05-19 English
Appendix 3B - Confirmation of Number of Shares Placed 8 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) form used for announcements related to new issues of securities, including placements and allotments of shares. The text includes details about the number of shares issued, the correction of a previously lodged Appendix 3B, and the application for quotation of additional securities. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about share issuance and capital changes. The document length is over 11,000 characters and contains detailed information about the securities issued, consistent with a share issue announcement. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2008-05-19 English
Change in substantial holding 6 pages ?Kb
Regulatory Filings
2008-05-11 English
POH Capital Raising of A$9.1m-App 3B and S708A Notice 10 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is a company announcement dated 07 May 2008 from Phosphagenics Limited regarding the completion of a capital raising of A$9.1 million through the placement of approximately 60.6 million shares. It includes detailed information about the share issue, terms, and regulatory notices such as Appendix 3B and a Section 708A notice under the Corporations Act 2001. The content focuses on the fundraising event, share issuance, and related regulatory compliance disclosures. There are no financial statements or comprehensive financial performance data presented, which rules out classifications like Annual Report (10-K) or Interim Report (IR). The document is not a simple announcement of a report publication but a substantive update on capital raising and share issuance. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2008-05-06 English
Trading Halt 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a market release dated 5 May 2008 from Phosphagenics Limited announcing a trading halt. The reason given is the expectation of a forthcoming announcement detailing the results of a capital raising. There is no financial data, report, or detailed analysis present. The document is short (1580 characters) and serves as a notification to the market about the trading halt pending a capital raising announcement. This fits the category of a Capital/Financing Update (CAP) as it relates to company fundraising activities.
2008-05-04 English
Positive Pre-clinical Results Targeted Delivery Lidocane 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 30 April 2008 from Phosphagenics Limited reporting positive pre-clinical results for a drug delivery technology involving lidocaine. It details study design, results, and includes quotes from company executives. The content is a press release about scientific and commercial progress rather than a financial report or regulatory filing. There are no financial statements, no mention of annual or quarterly results, no voting or governance information, no capital or financing updates, and no legal proceedings. The document is a corporate announcement about research and development progress, which does not fit into the specific financial or regulatory filing categories. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2008-04-29 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.